Identification of SEC61β and its autoantibody as biomarkers for colorectal cancer

Clinica Chimica Acta

Volumn 412, Issue 11-12, 2011, Pages 887-893

  Fan, Chung Wei ^a   Chan, Chung Chuan ^b,g   Chen, Kuei Tien ^c   Twu, Jen ^d   Huang, Ya Shu ^c   Han, Chia Li ^e   Chen, Yu Ju ^e   Yu, Jau Song ^c   Chang, Yu Sun ^c   Kuo, Yung Bin ^f   Chan, Err Cheng ^c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CATHAY GENERAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d CHINESE CULTURE UNIVERSITY   (Taiwan)

^e INSTITUTE OF CHEMISTRY   (Taiwan)

^f NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^g TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Autoantibody; Colorectal cancer; SEC61 ; Serological biomarker

Indexed keywords

AUTOANTIBODY; CARCINOEMBRYONIC ANTIGEN; CARRIER PROTEIN; PROTEIN SEC61BETA; PROTEIN SEC61BETA AUTOANTIBODY; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING;

AUTOANTIBODIES; CASE-CONTROL STUDIES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 79955049239     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2011.01.012     Document Type: Article

References (51)

1. Inger D.B. Colorectal cancer screening. Prim Care 1999, 26:179-187.
2. Ahlquist D.A. Fecal occult blood testing for colorectal cancer. Can we afford to do this?. Gastroenterol Clin North Am 1997, 26:41-55.
3. Collins J.F., Lieberman D.A., Durbin T.E., Weiss D.G. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med 2005, 142:81-85.
4. Geenen J.E., Schmitt M.G., Wu W.C., Hogan W.J. Major complications of coloscopy: bleeding and perforation. Am J Dig Dis 1975, 20:231-235.
5. Winawer S., Fletcher R., Rex D., et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 2003, 124:544-560.
6. Alessandro R., Belluco C., Kohn E.C. Proteomic approaches in colon cancer: promising tools for new cancer markers and drug target discovery. Clin Colorectal Cancer 2005, 4:396-402.
7. J.S. Chen, K.T. Chen, C.W. Fan, et al. Comparison of membrane fraction proteomic profiles of normal and cancerous human colorectal tissues with gel-assisted digestion and iTRAQ labeling mass spectrometry. FEBS J; 277:3028-3038.
8. Babel I., Barderas R., Diaz-Uriarte R., Martinez-Torrecuadrada J.L., Sanchez-Carbayo M., Casal J.I. Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays. Mol Cell Proteomics 2009, 8:2382-2395.
9. Tan E.M. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest 2001, 108:1411-1415.
10. Broll R., Duchrow M., Oevermann E., et al. p53 autoantibodies in sera of patients with a colorectal cancer and their association to p53 protein concentration and p53 immunohistochemistry in tumor tissue. Int J Colorectal Dis 2001, 16:22-27.
11. Chang S.C., Lin J.K., Lin T.C., Liang W.Y. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma. Int J Oncol 2005, 26:65-75.
12. Xia Q., Kong X.T., Zhang G.A., Hou X.J., Qiang H., Zhong R.Q. Proteomics-based identification of DEAD-box protein 48 as a novel autoantigen, a prospective serum marker for pancreatic cancer. Biochem Biophys Res Commun 2005, 330:526-532.
13. Reipert B.M., Tanneberger S., Pannetta A., et al. Increase in autoantibodies against Fas (CD95) during carcinogenesis in the human colon: a hope for the immunoprevention of cancer?. Cancer Immunol Immunother 2005, 54:1038-1042.
14. Hammel P., Boissier B., Chaumette M.T., et al. Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Gut 1997, 40:356-361.
15. Yagihashi A., Asanuma K., Kobayashi D., et al. Detection of autoantibodies to livin and survivin in sera from lung cancer patients. Lung Cancer 2005, 48:217-221.
16. Gorges R., Maniecki M., Jentzen W., et al. Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3years after thyroidectomy. Eur J Endocrinol 2005, 153:49-55.
17. Atalay C., Atalay G., Yilmaz K.B., Altinok M. The role of anti-CENP-B and anti-SS-B antibodies in breast cancer. Neoplasma 2005, 52:32-35.
18. Hudson M.E., Pozdnyakova I., Haines K., Mor G., Snyder M. Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc Natl Acad Sci USA 2007, 104:17494-17499.
19. Chapman C., Murray A., Chakrabarti J., et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 2007, 18:868-873.
20. Chapman C.J., Murray A., McElveen J.E., et al. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax 2008, 63:228-233.
21. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000, 60:1777-1788.
22. Chatterjee M., Mohapatra S., Ionan A., et al. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res 2006, 66:1181-1190.
23. Wang X., Yu J., Sreekumar A., et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005, 353:1224-1235.
24. Sreekumar A., Laxman B., Rhodes D.R., et al. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J Natl Cancer Inst 2004, 96:834-843.
25. Anderson K.S., LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 2005, 4:1123-1133.
26. Yamaguchi A., Kurosaka Y., Ishida T., et al. Clinical significance of tumor marker NCC-ST 439 in large bowel cancers. Dis Colon Rectum 1991, 34:921-924.
27. Gorlich D., Rapoport T.A. Protein translocation into proteoliposomes reconstituted from purified components of the endoplasmic reticulum membrane. Cell 1993, 75:615-630.
28. Rai A.J., Gelfand C.A., Haywood B.C., et al. HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 2005, 5:3262-3277.
29. Wu C.C., Chien K.Y., Tsang N.M., et al. Cancer cell-secreted proteomes as a basis for searching potential tumor markers: nasopharyngeal carcinoma as a model. Proteomics 2005, 5:3173-3182.
30. Ravn V., Rasmussen B.B., Hojholt L., Barfoed M., Heiberg I., Thorpe S.M. Reproducibility of subjective immunohistochemical estrogen- and progesterone receptor determination in human endometrium. Pathol Res Pract 1993, 189:1015-1022.
31. Chen Y., Lin P., Qiu S., et al. Autoantibodies to Ca2+ binding protein Calnuc is a potential marker in colon cancer detection. Int J Oncol 2007, 30:1137-1144.
32. Chen Y.T., Scanlan M.J., Sahin U., et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997, 94:1914-1918.
33. Schubert U., Anton L.C., Gibbs J., Norbury C.C., Yewdell J.W., Bennink J.R. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 2000, 404:770-774.
34. Ulanet D.B., Torbenson M., Dang C.V., Casciola-Rosen L., Rosen A. Unique conformation of cancer autoantigen B23 in hepatoma: a mechanism for specificity in the autoimmune response. Proc Natl Acad Sci USA 2003, 100:12361-12366.
35. von Mensdorff-Pouilly S., Petrakou E., Kenemans P., et al. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. Int J Cancer 2000, 86:702-712.
36. Lubin R., Zalcman G., Bouchet L., et al. Serum p53 antibodies as early markers of lung cancer. Nat Med 1995, 1:701-702.
37. Ralhan R., Nath N., Agarwal S., Mathur M., Wasylyk B., Shukla N.K. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations. Clin Cancer Res 1998, 4:2147-2152.
38. Disis M.L., Pupa S.M., Gralow J.R., Dittadi R., Menard S., Cheever M.A. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997, 15:3363-3367.
39. Duffy M.J., van Dalen A., Haglund C., et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007, 43:1348-1360.
40. Lu H., Goodell V., Disis M.L. Targeting serum antibody for cancer diagnosis: a focus on colorectal cancer. Expert Opin Ther Targets 2007, 11:235-244.
41. Angelopoulou K., Diamandis E.P., Sutherland D.J., Kellen J.A., Bunting P.S. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 1994, 58:480-487.
42. Angelopoulou K., Stratis M., Diamandis E.P. Humoral immune response against p53 protein in patients with colorectal carcinoma. Int J Cancer 1997, 70:46-51.
43. Tang R., Ko M.C., Wang J.Y., et al. Humoral response to p53 in human colorectal tumors: a prospective study of 1,209 patients. Int J Cancer 2001, 94:859-863.
44. Rohayem J., Diestelkoetter P., Weigle B., et al. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res 2000, 60:1815-1817.
45. Kocer B., McKolanis J., Soran A. Humoral immune response to MUC5AC in patients with colorectal polyps and colorectal carcinoma. BMC Gastroenterol 2006, 6:4.
46. Thomas P., Toth C.A., Saini K.S., Jessup J.M., Steele G. The structure, metabolism and function of the carcinoembryonic antigen gene family. Biochim Biophys Acta 1990, 1032:177-189.
47. Duffy M.J. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?. Clin Chem 2001, 47:624-630.
48. Wanebo H.J., Rao B., Pinsky C.M., et al. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med 1978, 299:448-451.
49. Mor G., Visintin I., Lai Y., et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci USA 2005, 102:7677-7682.
50. Hardcastle J.D., Chamberlain J.O., Robinson M.H., et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996, 348:1472-1477.
51. Kronborg O., Fenger C., Olsen J., Jorgensen O.D., Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996, 348:1467-1471.